JP2011518219A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518219A5 JP2011518219A5 JP2011506293A JP2011506293A JP2011518219A5 JP 2011518219 A5 JP2011518219 A5 JP 2011518219A5 JP 2011506293 A JP2011506293 A JP 2011506293A JP 2011506293 A JP2011506293 A JP 2011506293A JP 2011518219 A5 JP2011518219 A5 JP 2011518219A5
- Authority
- JP
- Japan
- Prior art keywords
- ylamino
- alkylene
- pyrrolo
- pyrimidin
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000002947 alkylene group Chemical group 0.000 claims 108
- -1 amino, hydroxy Chemical group 0.000 claims 60
- 125000003545 alkoxy group Chemical group 0.000 claims 42
- 125000000217 alkyl group Chemical group 0.000 claims 42
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 40
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 37
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 27
- 229910052799 carbon Inorganic materials 0.000 claims 25
- 125000000623 heterocyclic group Chemical group 0.000 claims 25
- 125000003118 aryl group Chemical group 0.000 claims 20
- 125000001475 halogen functional group Chemical group 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 125000004043 oxo group Chemical group O=* 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 15
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 8
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 6
- 125000006356 alkylene carbonyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000005237 alkyleneamino group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- VPQNMDJVVNHZTD-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-[4-(aminomethyl)piperidin-1-yl]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(N2CCC(CN)CC2)=C(C(=CN2)C#N)C2=N1 VPQNMDJVVNHZTD-UHFFFAOYSA-N 0.000 claims 3
- 102000042838 JAK family Human genes 0.000 claims 3
- 125000005001 aminoaryl group Chemical group 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 208000007056 sickle cell anemia Diseases 0.000 claims 3
- MFMUWALWYSDAIX-INIZCTEOSA-N (3s)-1-[2-(4-piperazin-1-ylanilino)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]pyrrolidin-3-ol Chemical compound C1[C@@H](O)CCN1C1=NC(NC=2C=CC(=CC=2)N2CCNCC2)=NC2=C1C=CN2 MFMUWALWYSDAIX-INIZCTEOSA-N 0.000 claims 2
- ISPIWMLOLHWBJV-UHFFFAOYSA-N 1-[2-(4-piperazin-1-ylanilino)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]piperidine-3-carboxamide Chemical compound C1C(C(=O)N)CCCN1C1=NC(NC=2C=CC(=CC=2)N2CCNCC2)=NC2=C1C=CN2 ISPIWMLOLHWBJV-UHFFFAOYSA-N 0.000 claims 2
- DSBLPCYZGDBXSG-UHFFFAOYSA-N 1-[2-(4-piperazin-1-ylanilino)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)N)CCN1C1=NC(NC=2C=CC(=CC=2)N2CCNCC2)=NC2=C1C=CN2 DSBLPCYZGDBXSG-UHFFFAOYSA-N 0.000 claims 2
- ITBJIOFDMUDQPI-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-fluoropyrimidin-4-yl]piperidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(N2CC(CCC2)C(N)=O)=N1 ITBJIOFDMUDQPI-UHFFFAOYSA-N 0.000 claims 2
- BKSBYMLCXXKXNA-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]piperidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(N2CC(CCC2)C(N)=O)=C(C=CN2)C2=N1 BKSBYMLCXXKXNA-UHFFFAOYSA-N 0.000 claims 2
- QORZSWGMEPAGEF-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]piperidine-4-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(N2CCC(CC2)C(N)=O)=C(C=CN2)C2=N1 QORZSWGMEPAGEF-UHFFFAOYSA-N 0.000 claims 2
- KLNYWORCDSBKLN-UHFFFAOYSA-N 1-[4-[4-[(4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(N2CCCCC2)=C(C=CN2)C2=N1 KLNYWORCDSBKLN-UHFFFAOYSA-N 0.000 claims 2
- XQNOAAQTRVPEJY-UHFFFAOYSA-N 1-[4-[4-[(4-pyrrolidin-1-yl-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(N2CCCC2)=C(C=CN2)C2=N1 XQNOAAQTRVPEJY-UHFFFAOYSA-N 0.000 claims 2
- IMBSTVSBJXHUBW-SFHVURJKSA-N 1-[4-[4-[[4-[(3s)-3-hydroxypyrrolidin-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(N2C[C@@H](O)CC2)=C(C=CN2)C2=N1 IMBSTVSBJXHUBW-SFHVURJKSA-N 0.000 claims 2
- UTOCZLMILKVPEA-UHFFFAOYSA-N 1-[4-[4-[[4-[2-(aminomethyl)piperidin-1-yl]-5-fluoropyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(N2C(CCCC2)CN)=N1 UTOCZLMILKVPEA-UHFFFAOYSA-N 0.000 claims 2
- AMHCKXVMDFGYGX-UHFFFAOYSA-N 1-[4-[4-[[4-[4-(aminomethyl)piperidin-1-yl]-5-fluoropyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(N2CCC(CN)CC2)=N1 AMHCKXVMDFGYGX-UHFFFAOYSA-N 0.000 claims 2
- NSCXCHDGMQTJCY-UHFFFAOYSA-N 1-[4-[4-[[4-[4-(aminomethyl)piperidin-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(N2CCC(CN)CC2)=C(C=CN2)C2=N1 NSCXCHDGMQTJCY-UHFFFAOYSA-N 0.000 claims 2
- IFHNDWIKIZOFSN-UHFFFAOYSA-N 1-[4-[4-[[6-[4-(aminomethyl)piperidin-1-yl]-7h-purin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(N2CCC(CN)CC2)=C(N=CN2)C2=N1 IFHNDWIKIZOFSN-UHFFFAOYSA-N 0.000 claims 2
- QNDRJTWJOGGLGW-UHFFFAOYSA-N 1-[5-fluoro-2-(1h-indazol-6-ylamino)pyrimidin-4-yl]piperidine-3-carboxamide Chemical compound C1C(C(=O)N)CCCN1C1=NC(NC=2C=C3NN=CC3=CC=2)=NC=C1F QNDRJTWJOGGLGW-UHFFFAOYSA-N 0.000 claims 2
- VMVVFAMYFKESAL-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-[4-(aminomethyl)piperidin-1-yl]pyrimidine-5-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(N2CCC(CN)CC2)=N1 VMVVFAMYFKESAL-UHFFFAOYSA-N 0.000 claims 2
- WSHBDAVXQWKPGV-UHFFFAOYSA-N 4-[4-(aminomethyl)piperidin-1-yl]-5-fluoro-n-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(C(F)=CN=2)N2CCC(CN)CC2)=C1 WSHBDAVXQWKPGV-UHFFFAOYSA-N 0.000 claims 2
- AIOJJUROCPYRGY-UHFFFAOYSA-N 4-[4-(aminomethyl)piperidin-1-yl]-n-(4-piperazin-1-ylphenyl)-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound C1CC(CN)CCN1C1=NC(NC=2C=CC(=CC=2)N2CCNCC2)=NC2=C1C=CN2 AIOJJUROCPYRGY-UHFFFAOYSA-N 0.000 claims 2
- CJZAKNKOVZAWIW-UHFFFAOYSA-N 6-[[4-[4-(aminomethyl)piperidin-1-yl]-5-fluoropyrimidin-2-yl]amino]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(CN)CCN1C1=NC(NC=2C=C3CCC(=O)NC3=CC=2)=NC=C1F CJZAKNKOVZAWIW-UHFFFAOYSA-N 0.000 claims 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 2
- 208000002903 Thalassemia Diseases 0.000 claims 2
- 125000006361 alkylene amino carbonyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- XZZALAYXCNVFOZ-UHFFFAOYSA-N methyl n-[4-[[4-(cyclobutylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-n-methylcarbamate Chemical compound C1=CC(N(C)C(=O)OC)=CC=C1NC1=NC(NC2CCC2)=C(C=CN2)C2=N1 XZZALAYXCNVFOZ-UHFFFAOYSA-N 0.000 claims 2
- RTPBRAGXGHSNGI-UHFFFAOYSA-N n-(4-piperazin-1-ylphenyl)-4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound C1CCCCN1C1=NC(NC=2C=CC(=CC=2)N2CCNCC2)=NC2=C1C=CN2 RTPBRAGXGHSNGI-UHFFFAOYSA-N 0.000 claims 2
- LGSSRXTZRZRCGP-UHFFFAOYSA-N n-(4-piperazin-1-ylphenyl)-4-pyrrolidin-1-yl-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound C1CCCN1C1=NC(NC=2C=CC(=CC=2)N2CCNCC2)=NC2=C1C=CN2 LGSSRXTZRZRCGP-UHFFFAOYSA-N 0.000 claims 2
- HQXXUQWPFMATCL-UHFFFAOYSA-N n-[4-[2-(aminomethyl)piperidin-1-yl]-5-fluoropyrimidin-2-yl]-1h-indazol-6-amine Chemical compound NCC1CCCCN1C1=NC(NC=2C=C3NN=CC3=CC=2)=NC=C1F HQXXUQWPFMATCL-UHFFFAOYSA-N 0.000 claims 2
- LUQJBQPCCBQITJ-UHFFFAOYSA-N n-[4-[4-(aminomethyl)piperidin-1-yl]-5-fluoropyrimidin-2-yl]-1h-indazol-6-amine Chemical compound C1CC(CN)CCN1C1=NC(NC=2C=C3NN=CC3=CC=2)=NC=C1F LUQJBQPCCBQITJ-UHFFFAOYSA-N 0.000 claims 2
- SMQOSQSCUMJLTB-UHFFFAOYSA-N n-[4-[[4-[4-(aminomethyl)piperidin-1-yl]-5-fluoropyrimidin-2-yl]amino]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC=C(F)C(N2CCC(CN)CC2)=N1 SMQOSQSCUMJLTB-UHFFFAOYSA-N 0.000 claims 2
- IKMBLWLVMKDJOW-UHFFFAOYSA-N tert-butyl n-[[1-[2-(4-carbamoylanilino)-5-fluoropyrimidin-4-yl]piperidin-4-yl]methyl]carbamate Chemical compound C1CC(CNC(=O)OC(C)(C)C)CCN1C1=NC(NC=2C=CC(=CC=2)C(N)=O)=NC=C1F IKMBLWLVMKDJOW-UHFFFAOYSA-N 0.000 claims 2
- RJPFULDFMSGSPC-UHFFFAOYSA-N tert-butyl n-[[1-[2-[4-[acetyl(methyl)amino]anilino]-5-fluoropyrimidin-4-yl]piperidin-4-yl]methyl]carbamate Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC=C(F)C(N2CCC(CNC(=O)OC(C)(C)C)CC2)=N1 RJPFULDFMSGSPC-UHFFFAOYSA-N 0.000 claims 2
- TWGVBXWKYXJGIH-UHFFFAOYSA-N tert-butyl n-[[1-[5-fluoro-2-(1h-indazol-6-ylamino)pyrimidin-4-yl]piperidin-2-yl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCCCN1C1=NC(NC=2C=C3NN=CC3=CC=2)=NC=C1F TWGVBXWKYXJGIH-UHFFFAOYSA-N 0.000 claims 2
- DTZXUJSOKGXUCS-CYBMUJFWSA-N (2r)-2-[[2-(4-piperazin-1-ylanilino)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]propan-1-ol Chemical compound N=1C=2NC=CC=2C(N[C@@H](CO)C)=NC=1NC(C=C1)=CC=C1N1CCNCC1 DTZXUJSOKGXUCS-CYBMUJFWSA-N 0.000 claims 1
- DTZXUJSOKGXUCS-ZDUSSCGKSA-N (2s)-2-[[2-(4-piperazin-1-ylanilino)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]propan-1-ol Chemical compound N=1C=2NC=CC=2C(N[C@H](CO)C)=NC=1NC(C=C1)=CC=C1N1CCNCC1 DTZXUJSOKGXUCS-ZDUSSCGKSA-N 0.000 claims 1
- 125000006636 (C3-C8) cycloalkylcarbonyl group Chemical group 0.000 claims 1
- XZGJAHQTUQUDGB-UHFFFAOYSA-N 1-[2-(4-piperazin-1-ylanilino)-7h-purin-6-yl]piperidine-3-carboxylic acid Chemical compound C1C(C(=O)O)CCCN1C1=NC(NC=2C=CC(=CC=2)N2CCNCC2)=NC2=C1N=CN2 XZGJAHQTUQUDGB-UHFFFAOYSA-N 0.000 claims 1
- QKXBGQYQXGMLCG-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-7h-purin-6-yl]piperidine-3-carboxylic acid Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(N2CC(CCC2)C(O)=O)=C(N=CN2)C2=N1 QKXBGQYQXGMLCG-UHFFFAOYSA-N 0.000 claims 1
- XNQDTXPMUWEHIU-UHFFFAOYSA-N 1-[4-(cyclopropylamino)-2-(1h-indazol-6-ylamino)-7h-pyrrolo[2,3-d]pyrimidin-5-yl]ethanone Chemical compound C=12C(C(=O)C)=CNC2=NC(NC=2C=C3NN=CC3=CC=2)=NC=1NC1CC1 XNQDTXPMUWEHIU-UHFFFAOYSA-N 0.000 claims 1
- YPPGEPDDWNRUCU-UHFFFAOYSA-N 1-[4-[4-[(5-fluoro-4-piperazin-1-ylpyrimidin-2-yl)amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(N2CCNCC2)=N1 YPPGEPDDWNRUCU-UHFFFAOYSA-N 0.000 claims 1
- UTBMAXNCUMKDHF-UHFFFAOYSA-N 1-[4-[4-[[4-(2-methoxyethylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound N=1C=2NC=CC=2C(NCCOC)=NC=1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 UTBMAXNCUMKDHF-UHFFFAOYSA-N 0.000 claims 1
- PRVQGVFQRVRVNF-UHFFFAOYSA-N 1-[4-[4-[[4-(4-aminopiperidin-1-yl)-5-fluoropyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(N2CCC(N)CC2)=N1 PRVQGVFQRVRVNF-UHFFFAOYSA-N 0.000 claims 1
- ZNOASPNIGDFOQH-UHFFFAOYSA-N 1-[4-[4-[[4-(cyclopropylamino)-5-pyridin-4-yl-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(NC2CC2)=C(C(=CN2)C=3C=CN=CC=3)C2=N1 ZNOASPNIGDFOQH-UHFFFAOYSA-N 0.000 claims 1
- PSFSHWDADXKQTD-UHFFFAOYSA-N 1-[4-[4-[[4-(methylamino)-5-pyridin-4-yl-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound N=1C=2NC=C(C=3C=CN=CC=3)C=2C(NC)=NC=1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 PSFSHWDADXKQTD-UHFFFAOYSA-N 0.000 claims 1
- XJTYNCJATWFGOR-UHFFFAOYSA-N 1-[4-[4-[[4-(piperidin-4-ylmethylamino)-5-pyridin-4-yl-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(NCC2CCNCC2)=C(C(=CN2)C=3C=CN=CC=3)C2=N1 XJTYNCJATWFGOR-UHFFFAOYSA-N 0.000 claims 1
- MFSDUZLYAOQMHU-KRWDZBQOSA-N 1-[4-[4-[[4-[(3s)-3-aminopiperidin-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(N2C[C@@H](N)CCC2)=C(C=CN2)C2=N1 MFSDUZLYAOQMHU-KRWDZBQOSA-N 0.000 claims 1
- PFQZSZKQBYZRGW-UHFFFAOYSA-N 1-[4-[4-[[4-[(4-aminocyclohexyl)amino]-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(NC2CCC(N)CC2)=C(C=CN2)C2=N1 PFQZSZKQBYZRGW-UHFFFAOYSA-N 0.000 claims 1
- AXPRUMVDNQHMHM-UHFFFAOYSA-N 1-[4-[4-[[4-[4-(aminomethyl)piperidin-1-yl]-5-chloropyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(Cl)C(N2CCC(CN)CC2)=N1 AXPRUMVDNQHMHM-UHFFFAOYSA-N 0.000 claims 1
- WVGLLIMUMJTKGE-CQSZACIVSA-N 1-[4-[4-[[4-[[(2r)-1-hydroxypropan-2-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound N=1C=2NC=CC=2C(N[C@@H](CO)C)=NC=1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 WVGLLIMUMJTKGE-CQSZACIVSA-N 0.000 claims 1
- WVGLLIMUMJTKGE-AWEZNQCLSA-N 1-[4-[4-[[4-[[(2s)-1-hydroxypropan-2-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound N=1C=2NC=CC=2C(N[C@H](CO)C)=NC=1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 WVGLLIMUMJTKGE-AWEZNQCLSA-N 0.000 claims 1
- KCWJGNYVKTXHCU-UHFFFAOYSA-N 1-[4-[4-[[5-fluoro-4-[4-(hydroxymethyl)piperidin-1-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(N2CCC(CO)CC2)=N1 KCWJGNYVKTXHCU-UHFFFAOYSA-N 0.000 claims 1
- JTHRAEIOHKMUAR-UHFFFAOYSA-N 1-[4-[[4-(cyclobutylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound C1CC(O)CCN1C(C=C1)=CC=C1NC1=NC(NC2CCC2)=C(C=CN2)C2=N1 JTHRAEIOHKMUAR-UHFFFAOYSA-N 0.000 claims 1
- DHKNMIIKOXMEOH-UHFFFAOYSA-N 1-[4-[[4-(cyclobutylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]sulfonylpiperidin-4-ol Chemical compound C1CC(O)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC(NC2CCC2)=C(C=CN2)C2=N1 DHKNMIIKOXMEOH-UHFFFAOYSA-N 0.000 claims 1
- XNULAWSAHRUNPA-UHFFFAOYSA-N 2-(1H-indazol-6-yl)-1,7-dihydropyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound N1N=CC2=CC=C(C=C12)C1(N=C(C2=C(N1)NC=C2)N)N XNULAWSAHRUNPA-UHFFFAOYSA-N 0.000 claims 1
- SGRFFLBYAQNWOE-UHFFFAOYSA-N 2-N'-(1H-indazol-6-yl)-1,7-dihydropyrrolo[2,3-d]pyrimidine-2,2,4-triamine Chemical compound N1N=CC2=CC=C(C=C12)NC1(N=C(C2=C(N1)NC=C2)N)N SGRFFLBYAQNWOE-UHFFFAOYSA-N 0.000 claims 1
- WIQRWQXZZNVZFL-UHFFFAOYSA-N 2-[1-[2-[(2-oxo-3,4-dihydro-1h-quinolin-6-yl)amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]piperidin-4-yl]acetic acid Chemical compound C1CC(CC(=O)O)CCN1C1=NC(NC=2C=C3CCC(=O)NC3=CC=2)=NC2=C1C=CN2 WIQRWQXZZNVZFL-UHFFFAOYSA-N 0.000 claims 1
- OUNCMUFBHHDXDZ-UHFFFAOYSA-N 2-[1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-fluoropyrimidin-4-yl]piperidin-4-yl]acetamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(N2CCC(CC(N)=O)CC2)=N1 OUNCMUFBHHDXDZ-UHFFFAOYSA-N 0.000 claims 1
- FPDOGAOCLXKEHW-UHFFFAOYSA-O 2-[3-(4-aminophenyl)imidazol-1-ium-1-yl]-4-(cyclopropylamino)pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=C([N+]2=CN(C=C2)C=2C=CC(N)=CC=2)N=C1NC1CC1 FPDOGAOCLXKEHW-UHFFFAOYSA-O 0.000 claims 1
- INHNRAOOPAMPNA-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-(cyclopropylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(NC2CC2)=C(C(=CN2)C#N)C2=N1 INHNRAOOPAMPNA-UHFFFAOYSA-N 0.000 claims 1
- YZAMAONAYMDYCQ-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-(piperidin-4-ylmethylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(NCC2CCNCC2)=C(C(=CN2)C#N)C2=N1 YZAMAONAYMDYCQ-UHFFFAOYSA-N 0.000 claims 1
- HUQPDXIUYNLBPK-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-[4-[(carbamoylamino)methyl]piperidin-1-yl]pyrimidine-5-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(N2CCC(CNC(N)=O)CC2)=N1 HUQPDXIUYNLBPK-UHFFFAOYSA-N 0.000 claims 1
- LDBJYWUOPXAMJZ-UHFFFAOYSA-O 2-[4-(4-aminophenyl)pyridin-1-ium-1-yl]-4-(cyclopropylamino)pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=C([N+]=2C=CC(=CC=2)C=2C=CC(N)=CC=2)N=C1NC1CC1 LDBJYWUOPXAMJZ-UHFFFAOYSA-O 0.000 claims 1
- DNXQUONSOHUEFK-UHFFFAOYSA-N 2-[6-[[4-(cyclobutylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-2-oxo-3,4-dihydroquinolin-1-yl]acetic acid Chemical compound C=1C=C2N(CC(=O)O)C(=O)CCC2=CC=1NC(N=C1NC=CC1=1)=NC=1NC1CCC1 DNXQUONSOHUEFK-UHFFFAOYSA-N 0.000 claims 1
- MWRMPCHAICBCFB-UHFFFAOYSA-N 2-[[4-[[4-(cyclobutylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]sulfonyl-methylamino]acetic acid Chemical compound C1=CC(S(=O)(=O)N(CC(O)=O)C)=CC=C1NC1=NC(NC2CCC2)=C(C=CN2)C2=N1 MWRMPCHAICBCFB-UHFFFAOYSA-N 0.000 claims 1
- LYUSDPQLOXYNQI-UHFFFAOYSA-N 2-n-(1h-indazol-6-yl)-4-n-(3-morpholin-4-ylpropyl)-7h-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound N=1C(NC=2C=C3NN=CC3=CC=2)=NC=2NC=CC=2C=1NCCCN1CCOCC1 LYUSDPQLOXYNQI-UHFFFAOYSA-N 0.000 claims 1
- YLMFCAFPWOCZSU-UHFFFAOYSA-N 2-n-(1h-indazol-6-yl)-4-n-methyl-5-pyridin-3-yl-7h-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound C1=2C(NC)=NC(NC=3C=C4NN=CC4=CC=3)=NC=2NC=C1C1=CC=CN=C1 YLMFCAFPWOCZSU-UHFFFAOYSA-N 0.000 claims 1
- IOKYKLYLSOUELK-UHFFFAOYSA-N 2-n-(1h-indazol-6-yl)-4-n-methyl-5-pyridin-4-yl-7h-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound C1=2C(NC)=NC(NC=3C=C4NN=CC4=CC=3)=NC=2NC=C1C1=CC=NC=C1 IOKYKLYLSOUELK-UHFFFAOYSA-N 0.000 claims 1
- ZILHMIGQJBOTJU-UHFFFAOYSA-N 2-n-(1h-indazol-6-yl)-4-n-piperidin-4-yl-7h-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound C1CNCCC1NC1=NC(NC=2C=C3NN=CC3=CC=2)=NC2=C1C=CN2 ZILHMIGQJBOTJU-UHFFFAOYSA-N 0.000 claims 1
- KHILDJMDZDCFIM-UHFFFAOYSA-N 3-[4-[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]-3-oxopropanenitrile Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(N2CCN(CC2)C(=O)CC#N)=N1 KHILDJMDZDCFIM-UHFFFAOYSA-N 0.000 claims 1
- XRPNJXNZMNEFBT-UHFFFAOYSA-N 3-[[2-[4-(4-acetylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]benzamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(NC=2C=C(C=CC=2)C(N)=O)=C(C=CN2)C2=N1 XRPNJXNZMNEFBT-UHFFFAOYSA-N 0.000 claims 1
- SJUVCARONIQDPU-UHFFFAOYSA-N 3-[[2-[4-(4-acetylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]benzenesulfonamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC(NC=2C=C(C=CC=2)S(N)(=O)=O)=C(C=CN2)C2=N1 SJUVCARONIQDPU-UHFFFAOYSA-N 0.000 claims 1
- CVAZHNFIOMSNTF-UHFFFAOYSA-N 4-(4-methoxyanilino)-2-[(2-oxo-3,4-dihydro-1h-quinolin-6-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1NC1=NC(NC=2C=C3CCC(=O)NC3=CC=2)=NC2=C1C(C#N)=CN2 CVAZHNFIOMSNTF-UHFFFAOYSA-N 0.000 claims 1
- IZFWMBQWJLCGRI-UHFFFAOYSA-N 4-(benzylamino)-2-[(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound C=1C=C2N(C)C(=O)CCC2=CC=1NC(N=C1NC=C(C1=1)C#N)=NC=1NCC1=CC=CC=C1 IZFWMBQWJLCGRI-UHFFFAOYSA-N 0.000 claims 1
- MQBFQWRJAMUKER-UHFFFAOYSA-N 4-(cyclobutylamino)-2-(1h-indazol-6-ylamino)-6,7-dihydropyrrolo[2,3-d]pyrimidin-5-one Chemical compound C=12C(=O)CNC2=NC(NC=2C=C3NN=CC3=CC=2)=NC=1NC1CCC1 MQBFQWRJAMUKER-UHFFFAOYSA-N 0.000 claims 1
- FKBFTAHPPHQKHW-UHFFFAOYSA-N 4-(cyclopropylamino)-2-(1h-indazol-6-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound C=12C(C#N)=CNC2=NC(NC=2C=C3NN=CC3=CC=2)=NC=1NC1CC1 FKBFTAHPPHQKHW-UHFFFAOYSA-N 0.000 claims 1
- DWLXOZFJWNKMTA-UHFFFAOYSA-N 4-(cyclopropylamino)-2-[(2-oxo-3,4-dihydro-1h-quinolin-6-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound C=1C=C2NC(=O)CCC2=CC=1NC(N=C1NC=C(C1=1)C#N)=NC=1NC1CC1 DWLXOZFJWNKMTA-UHFFFAOYSA-N 0.000 claims 1
- LQUFEFDXJHVJER-UHFFFAOYSA-N 4-(cyclopropylamino)-2-[(2-oxo-3,4-dihydro-1h-quinolin-6-yl)amino]-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide Chemical compound C=12C(C(=O)N)=CNC2=NC(NC=2C=C3CCC(=O)NC3=CC=2)=NC=1NC1CC1 LQUFEFDXJHVJER-UHFFFAOYSA-N 0.000 claims 1
- BYAABDGMFIJTGO-ZDUSSCGKSA-N 4-[(2s)-2-(aminomethyl)pyrrolidin-1-yl]-n-(1h-indazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound NC[C@@H]1CCCN1C1=NC(NC=2C=C3NN=CC3=CC=2)=NC2=C1C=CN2 BYAABDGMFIJTGO-ZDUSSCGKSA-N 0.000 claims 1
- VHWAWQGJURZMQB-UHFFFAOYSA-N 4-[(4-amino-5-pyridin-4-yl-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino]benzoic acid Chemical compound N=1C=2NC=C(C=3C=CN=CC=3)C=2C(N)=NC=1NC1=CC=C(C(O)=O)C=C1 VHWAWQGJURZMQB-UHFFFAOYSA-N 0.000 claims 1
- WICMQZFDKXYPCK-UHFFFAOYSA-N 4-[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-fluoropyrimidin-4-yl]piperazine-1-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(N2CCN(CC2)C(N)=O)=N1 WICMQZFDKXYPCK-UHFFFAOYSA-N 0.000 claims 1
- NQYHQKSIEQVZFT-UHFFFAOYSA-N 4-[[4-(cyclopropylamino)-5-pyridin-4-yl-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1NC1=NC(NC2CC2)=C(C(=CN2)C=3C=CN=CC=3)C2=N1 NQYHQKSIEQVZFT-UHFFFAOYSA-N 0.000 claims 1
- WKIQOCLSDNSELN-UHFFFAOYSA-N 4-[[4-[4-(aminomethyl)piperidin-1-yl]-5-fluoropyrimidin-2-yl]amino]benzamide Chemical compound C1CC(CN)CCN1C1=NC(NC=2C=CC(=CC=2)C(N)=O)=NC=C1F WKIQOCLSDNSELN-UHFFFAOYSA-N 0.000 claims 1
- FJZSYCRTFSDIJP-UHFFFAOYSA-N 4-[[4-[4-(aminomethyl)piperidin-1-yl]-5-fluoropyrimidin-2-yl]amino]benzoic acid Chemical compound C1CC(CN)CCN1C1=NC(NC=2C=CC(=CC=2)C(O)=O)=NC=C1F FJZSYCRTFSDIJP-UHFFFAOYSA-N 0.000 claims 1
- CFUQUMNDXZYNSK-UHFFFAOYSA-N 4-[[4-[[1-(2-cyanoacetyl)piperidin-3-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1NC1=NC(NC2CN(CCC2)C(=O)CC#N)=C(C=CN2)C2=N1 CFUQUMNDXZYNSK-UHFFFAOYSA-N 0.000 claims 1
- SBDWLPPYBIFYSR-UHFFFAOYSA-N 4-[[4-[[1-(2-cyanoacetyl)piperidin-4-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1NC1=NC(NC2CCN(CC2)C(=O)CC#N)=C(C=CN2)C2=N1 SBDWLPPYBIFYSR-UHFFFAOYSA-N 0.000 claims 1
- BEUOVQXMNPBPSS-UHFFFAOYSA-N 4-[[5-cyano-4-(cyclopropylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1NC1=NC(NC2CC2)=C(C(=CN2)C#N)C2=N1 BEUOVQXMNPBPSS-UHFFFAOYSA-N 0.000 claims 1
- LVDKECMPJSIFIM-UHFFFAOYSA-N 4-[[5-cyano-4-(cyclopropylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC(NC2CC2)=C(C(=CN2)C#N)C2=N1 LVDKECMPJSIFIM-UHFFFAOYSA-N 0.000 claims 1
- ZTRCPJUJRGXEHU-UHFFFAOYSA-N 4-n-(3-amino-2,2-dimethylpropyl)-2-n-(1h-indazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound C1=C2C=NNC2=CC(NC=2N=C(C=3C=CNC=3N=2)NCC(C)(CN)C)=C1 ZTRCPJUJRGXEHU-UHFFFAOYSA-N 0.000 claims 1
- JNTKFSIDPKWDSN-UHFFFAOYSA-N 4-n-cyclobutyl-2-n-(1h-indazol-6-yl)-6-methyl-7h-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound N1=C(NC=2C=C3NN=CC3=CC=2)N=C2NC(C)=CC2=C1NC1CCC1 JNTKFSIDPKWDSN-UHFFFAOYSA-N 0.000 claims 1
- GGNMOPIIZOOFOU-UHFFFAOYSA-N 4-n-cyclopropyl-2-n-(1h-indazol-6-yl)-5-pyridin-4-yl-7h-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound C1CC1NC1=NC(NC=2C=C3NN=CC3=CC=2)=NC2=C1C(C=1C=CN=CC=1)=CN2 GGNMOPIIZOOFOU-UHFFFAOYSA-N 0.000 claims 1
- IVNMJIBLDUFADM-UHFFFAOYSA-N 5-(1-butoxyethyl)-4-n-cyclopropyl-2-n-(1h-indazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound C=12C(C(C)OCCCC)=CNC2=NC(NC=2C=C3NN=CC3=CC=2)=NC=1NC1CC1 IVNMJIBLDUFADM-UHFFFAOYSA-N 0.000 claims 1
- HUHDFRIJLCSUAX-UHFFFAOYSA-N 5-bromo-4-n-cyclobutyl-2-n-(1h-indazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound C=12C(Br)=CNC2=NC(NC=2C=C3NN=CC3=CC=2)=NC=1NC1CCC1 HUHDFRIJLCSUAX-UHFFFAOYSA-N 0.000 claims 1
- XPQGSTKWZSZQOO-UHFFFAOYSA-N 5-chloro-4-n-cyclobutyl-2-n-(1h-indazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound C=12C(Cl)=CNC2=NC(NC=2C=C3NN=CC3=CC=2)=NC=1NC1CCC1 XPQGSTKWZSZQOO-UHFFFAOYSA-N 0.000 claims 1
- KPJAHCMJJYTGPJ-UHFFFAOYSA-N 6-[[4-(4-fluoroanilino)-5-pyridin-4-yl-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-1-methyl-3,4-dihydroquinolin-2-one Chemical compound C=1C=C2N(C)C(=O)CCC2=CC=1NC(N=C1NC=C(C1=1)C=2C=CN=CC=2)=NC=1NC1=CC=C(F)C=C1 KPJAHCMJJYTGPJ-UHFFFAOYSA-N 0.000 claims 1
- AISCZGQJJMKZFS-UHFFFAOYSA-N 6-[[4-(cyclopropylamino)-5-pyridin-4-yl-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-3,4-dihydro-1h-quinolin-2-one Chemical compound C=1C=C2NC(=O)CCC2=CC=1NC(N=C1NC=C(C1=1)C=2C=CN=CC=2)=NC=1NC1CC1 AISCZGQJJMKZFS-UHFFFAOYSA-N 0.000 claims 1
- OVWJXOACFMZFDO-UHFFFAOYSA-N 6-[[4-[4-(aminomethyl)piperidin-1-yl]-5-bromopyrimidin-2-yl]amino]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(CN)CCN1C1=NC(NC=2C=C3CCC(=O)NC3=CC=2)=NC=C1Br OVWJXOACFMZFDO-UHFFFAOYSA-N 0.000 claims 1
- XCAXBGZQTWYZKQ-UHFFFAOYSA-N 6-[[4-[4-(aminomethyl)piperidin-1-yl]-5-cyclopropylpyrimidin-2-yl]amino]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(CN)CCN1C1=NC(NC=2C=C3CCC(=O)NC3=CC=2)=NC=C1C1CC1 XCAXBGZQTWYZKQ-UHFFFAOYSA-N 0.000 claims 1
- JUZQBHPATZXEBX-UHFFFAOYSA-N 6-[[4-[4-(aminomethyl)piperidin-1-yl]-5-pyridin-4-ylpyrimidin-2-yl]amino]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(CN)CCN1C1=NC(NC=2C=C3CCC(=O)NC3=CC=2)=NC=C1C1=CC=NC=C1 JUZQBHPATZXEBX-UHFFFAOYSA-N 0.000 claims 1
- NROHJGQGAQGIQO-UHFFFAOYSA-N 6-[[4-amino-5-(4-fluorophenyl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-1-methyl-3,4-dihydroquinolin-2-one Chemical compound C=1C=C2N(C)C(=O)CCC2=CC=1NC(N=C1NC=2)=NC(N)=C1C=2C1=CC=C(F)C=C1 NROHJGQGAQGIQO-UHFFFAOYSA-N 0.000 claims 1
- MYGMMIDGBHQQHM-UHFFFAOYSA-N 6-[[5-fluoro-4-(3-oxopiperazin-1-yl)pyrimidin-2-yl]amino]-3,4-dihydro-1h-quinolin-2-one Chemical compound FC1=CN=C(NC=2C=C3CCC(=O)NC3=CC=2)N=C1N1CCNC(=O)C1 MYGMMIDGBHQQHM-UHFFFAOYSA-N 0.000 claims 1
- CPRNMNCLUWFPAY-UHFFFAOYSA-N 6-[[5-fluoro-4-[4-(hydroxymethyl)piperidin-1-yl]pyrimidin-2-yl]amino]-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(CO)CCN1C1=NC(NC=2C=C3CCC(=O)NC3=CC=2)=NC=C1F CPRNMNCLUWFPAY-UHFFFAOYSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000009336 Hemoglobin SC Disease Diseases 0.000 claims 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000035868 Vascular inflammations Diseases 0.000 claims 1
- MBVTXFLBVWGZKZ-UHFFFAOYSA-N [1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-fluoropyrimidin-4-yl]piperidin-4-yl]urea Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(N2CCC(CC2)NC(N)=O)=N1 MBVTXFLBVWGZKZ-UHFFFAOYSA-N 0.000 claims 1
- JCDGOMWJDYEMRD-UHFFFAOYSA-N [1-[5-fluoro-2-[(2-oxo-3,4-dihydro-1h-quinolin-6-yl)amino]pyrimidin-4-yl]piperidin-4-yl]methylurea Chemical compound C1CC(CNC(=O)N)CCN1C1=NC(NC=2C=C3CCC(=O)NC3=CC=2)=NC=C1F JCDGOMWJDYEMRD-UHFFFAOYSA-N 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000005275 alkylenearyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- XUCXRBYKWJQBCR-UHFFFAOYSA-N benzyl n-[1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-fluoropyrimidin-4-yl]piperidin-4-yl]carbamate Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(N2CCC(CC2)NC(=O)OCC=2C=CC=CC=2)=N1 XUCXRBYKWJQBCR-UHFFFAOYSA-N 0.000 claims 1
- 230000005266 beta plus decay Effects 0.000 claims 1
- WRNQZUSHXRJOFV-UHFFFAOYSA-N butyl 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-7h-purin-6-yl]piperidine-3-carboxylate Chemical compound C1C(C(=O)OCCCC)CCCN1C1=NC(NC=2C=CC(=CC=2)N2CCN(CC2)C(C)=O)=NC2=C1N=CN2 WRNQZUSHXRJOFV-UHFFFAOYSA-N 0.000 claims 1
- ZJXMKHTZXDPMTI-UHFFFAOYSA-N butyl 2-[[4-[[4-(cyclobutylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]sulfonyl-methylamino]acetate Chemical compound C1=CC(S(=O)(=O)N(C)CC(=O)OCCCC)=CC=C1NC1=NC(NC2CCC2)=C(C=CN2)C2=N1 ZJXMKHTZXDPMTI-UHFFFAOYSA-N 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- VDOLLKKRULNHHS-UHFFFAOYSA-N ethyl 3-amino-3-[1-[5-fluoro-2-[(2-oxo-3,4-dihydro-1h-quinolin-6-yl)amino]pyrimidin-4-yl]piperidin-4-yl]propanoate Chemical compound C1CC(C(N)CC(=O)OCC)CCN1C1=NC(NC=2C=C3CCC(=O)NC3=CC=2)=NC=C1F VDOLLKKRULNHHS-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- GSPPNZDCNBEHKN-UHFFFAOYSA-N methyl 2-amino-2-[1-[5-fluoro-2-[(2-oxo-3,4-dihydro-1h-quinolin-6-yl)amino]pyrimidin-4-yl]piperidin-4-yl]acetate Chemical compound C1CC(C(N)C(=O)OC)CCN1C1=NC(NC=2C=C3CCC(=O)NC3=CC=2)=NC=C1F GSPPNZDCNBEHKN-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- MMFWGWJLDNYCMK-UHFFFAOYSA-N n-[1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-fluoropyrimidin-4-yl]piperidin-4-yl]-2-cyanoacetamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(F)C(N2CCC(CC2)NC(=O)CC#N)=N1 MMFWGWJLDNYCMK-UHFFFAOYSA-N 0.000 claims 1
- JXFKDPBYKMLALY-UHFFFAOYSA-N n-[4-[[4-(2-aminoethylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC(NCCN)=C(C=CN2)C2=N1 JXFKDPBYKMLALY-UHFFFAOYSA-N 0.000 claims 1
- ZDVKZCCNACCXMY-UHFFFAOYSA-N n-[4-[[4-(5-aminopentylamino)-5,6-dibromo-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC(NCCCCCN)=C(C(Br)=C(Br)N2)C2=N1 ZDVKZCCNACCXMY-UHFFFAOYSA-N 0.000 claims 1
- BOOFPRYOARKZNQ-UHFFFAOYSA-N n-[4-[[4-(5-aminopentylamino)-5-bromo-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC(NCCCCCN)=C(C(Br)=CN2)C2=N1 BOOFPRYOARKZNQ-UHFFFAOYSA-N 0.000 claims 1
- QNJACHBPWBMEOL-UHFFFAOYSA-N n-[4-[[4-(5-aminopentylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC(NCCCCCN)=C(C=CN2)C2=N1 QNJACHBPWBMEOL-UHFFFAOYSA-N 0.000 claims 1
- RVVQGBSLKLEOCY-UHFFFAOYSA-N n-[4-[[4-(cyclobutylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-2-(dimethylamino)-n-methylacetamide Chemical compound C1=CC(N(C)C(=O)CN(C)C)=CC=C1NC1=NC(NC2CCC2)=C(C=CN2)C2=N1 RVVQGBSLKLEOCY-UHFFFAOYSA-N 0.000 claims 1
- WWCCTGSLIZXDTL-UHFFFAOYSA-N n-[4-[[4-(cyclobutylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-2-hydroxy-n-methylacetamide Chemical compound C1=CC(N(C(=O)CO)C)=CC=C1NC1=NC(NC2CCC2)=C(C=CN2)C2=N1 WWCCTGSLIZXDTL-UHFFFAOYSA-N 0.000 claims 1
- SWHRJPVJYXUCQS-UHFFFAOYSA-N n-[4-[[4-(cyclobutylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-3-hydroxy-n-methylpropanamide Chemical compound C1=CC(N(C(=O)CCO)C)=CC=C1NC1=NC(NC2CCC2)=C(C=CN2)C2=N1 SWHRJPVJYXUCQS-UHFFFAOYSA-N 0.000 claims 1
- UPJOJLGLIPQOBK-UHFFFAOYSA-N n-[4-[[4-(cyclobutylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-n-methylcyclopropanecarboxamide Chemical compound C=1C=C(NC=2N=C3NC=CC3=C(NC3CCC3)N=2)C=CC=1N(C)C(=O)C1CC1 UPJOJLGLIPQOBK-UHFFFAOYSA-N 0.000 claims 1
- JCTXRAMVSVUQQS-UHFFFAOYSA-N n-[4-[[4-(cyclopropylamino)-5-pyridin-4-yl-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC(NC2CC2)=C(C(=CN2)C=3C=CN=CC=3)C2=N1 JCTXRAMVSVUQQS-UHFFFAOYSA-N 0.000 claims 1
- NUERPOSUPKZQTM-UHFFFAOYSA-N n-[4-[[4-(cyclopropylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-2-hydroxy-n-methylacetamide Chemical compound C1=CC(N(C(=O)CO)C)=CC=C1NC1=NC(NC2CC2)=C(C=CN2)C2=N1 NUERPOSUPKZQTM-UHFFFAOYSA-N 0.000 claims 1
- KVPUICDCYACAEH-UHFFFAOYSA-N n-[4-[[4-(cyclopropylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-3-hydroxy-n-methylpropanamide Chemical compound C1=CC(N(C(=O)CCO)C)=CC=C1NC1=NC(NC2CC2)=C(C=CN2)C2=N1 KVPUICDCYACAEH-UHFFFAOYSA-N 0.000 claims 1
- ONLWFBZONSCPIG-UHFFFAOYSA-N n-[4-[[4-(cyclopropylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-n-methylcyclopropanecarboxamide Chemical compound C=1C=C(NC=2N=C3NC=CC3=C(NC3CC3)N=2)C=CC=1N(C)C(=O)C1CC1 ONLWFBZONSCPIG-UHFFFAOYSA-N 0.000 claims 1
- MRWSDBSJWQCJDN-UHFFFAOYSA-N n-[4-[[4-[(2-aminocyclohexyl)amino]-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC(NC2C(CCCC2)N)=C(C=CN2)C2=N1 MRWSDBSJWQCJDN-UHFFFAOYSA-N 0.000 claims 1
- UXSGPZDPBYUYPW-UHFFFAOYSA-N n-[4-[[4-[3-(aminomethyl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC(NC=2C=C(CN)C=CC=2)=C(C=CN2)C2=N1 UXSGPZDPBYUYPW-UHFFFAOYSA-N 0.000 claims 1
- FXGNYOJHHQDFFW-UHFFFAOYSA-N n-[4-[[5-cyano-4-(cyclopropylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-n-methylacetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC(NC2CC2)=C(C(=CN2)C#N)C2=N1 FXGNYOJHHQDFFW-UHFFFAOYSA-N 0.000 claims 1
- TXXRZNTYCZIBMY-UHFFFAOYSA-N n-methyl-n-[4-[[4-(3-sulfamoylanilino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]acetamide Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=NC(NC=2C=C(C=CC=2)S(N)(=O)=O)=C(C=CN2)C2=N1 TXXRZNTYCZIBMY-UHFFFAOYSA-N 0.000 claims 1
- VWNMJAVLAOVLFP-UHFFFAOYSA-N n-methyl-n-[4-[[4-(methylamino)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound N=1C=2NC=CC=2C(NC)=NC=1NC(C=C1)=CC=C1N(C)C(=O)C1CC1 VWNMJAVLAOVLFP-UHFFFAOYSA-N 0.000 claims 1
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- SYVHWMDUHHIEJL-UHFFFAOYSA-N tert-butyl 4-[[2-(1h-indazol-6-ylamino)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=NC(NC=2C=C3NN=CC3=CC=2)=NC2=C1C=CN2 SYVHWMDUHHIEJL-UHFFFAOYSA-N 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 0 C*(*)*CN(*)c1nc(N(*)*#C)c(*(*)(*)C(*)N2*)c2n1 Chemical compound C*(*)*CN(*)c1nc(N(*)*#C)c(*(*)(*)C(*)N2*)c2n1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4707708P | 2008-04-22 | 2008-04-22 | |
| US61/047,077 | 2008-04-22 | ||
| PCT/US2009/002512 WO2009131687A2 (en) | 2008-04-22 | 2009-04-22 | Inhibitors of protein kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011518219A JP2011518219A (ja) | 2011-06-23 |
| JP2011518219A5 true JP2011518219A5 (cg-RX-API-DMAC10.html) | 2012-06-14 |
Family
ID=40910850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011506293A Withdrawn JP2011518219A (ja) | 2008-04-22 | 2009-04-22 | タンパク質キナーゼの阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8258144B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2271631B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2011518219A (cg-RX-API-DMAC10.html) |
| CN (2) | CN102066338A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2009238590A1 (cg-RX-API-DMAC10.html) |
| BR (1) | BRPI0910668A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2723185A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL208719A0 (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ588830A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2009131687A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (173)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090082507A (ko) | 2006-11-20 | 2009-07-30 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 통증 및 소양증 치료용 방법, 조성물 및 키트 |
| US8252803B2 (en) * | 2007-02-12 | 2012-08-28 | Merck Sharp & Dohme Corp. | Piperidine derivatives |
| WO2015164330A1 (en) | 2014-04-21 | 2015-10-29 | Millennium Pharmaceuticals, Inc. | Anti-psyk antibody molecules and use of same for syk-targeted therapy |
| US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| AU2009259853A1 (en) * | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine JAK inhibitor compounds and methods |
| PE20110063A1 (es) * | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
| TW201016676A (en) * | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| US8242248B2 (en) * | 2009-03-23 | 2012-08-14 | Nodality, Inc. | Kits for multiparametric phospho analysis |
| WO2011006073A1 (en) | 2009-07-10 | 2011-01-13 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| AU2011218167B2 (en) * | 2010-02-17 | 2014-07-10 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| TWI513694B (zh) | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
| JP5744021B2 (ja) | 2010-06-30 | 2015-07-01 | 富士フイルム株式会社 | 新規なニコチンアミド誘導体またはその塩 |
| US9586961B2 (en) | 2010-07-09 | 2017-03-07 | Leo Pharma A/S | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| CN102372717B (zh) * | 2010-08-20 | 2014-06-18 | 和记黄埔医药（上海）有限公司 | 吡咯并嘧啶类化合物及其用途 |
| AU2011323484B2 (en) * | 2010-11-01 | 2016-10-06 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as Syk modulators |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| CN103476776B (zh) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
| CN102093364B (zh) | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
| EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| US20140005188A1 (en) * | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| KR101606250B1 (ko) * | 2011-03-23 | 2016-03-24 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
| TWI548621B (zh) | 2011-04-22 | 2016-09-11 | 標誌製藥公司 | 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法 |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| CA2834062A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
| WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
| AU2012253885A1 (en) | 2011-05-10 | 2013-10-31 | Merck Sharp & Dohme Corp. | Aminopyrimidines as Syk inhibitors |
| EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| US8987456B2 (en) | 2011-10-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| WO2013052391A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| EP2782579B1 (en) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
| DK2799431T3 (en) | 2011-12-28 | 2018-03-26 | Fujifilm Corp | Hitherto unknown nicotinamide derivatives or salts thereof |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| CA2861010A1 (en) | 2012-01-13 | 2013-07-18 | Xiao Xu | Heterocyclic compounds and uses as anticancer agents |
| US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
| US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| WO2013192125A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| EP2863913B1 (en) | 2012-06-20 | 2018-09-12 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
| WO2013192088A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| US9376418B2 (en) | 2012-06-22 | 2016-06-28 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors |
| EA025186B1 (ru) | 2012-06-29 | 2016-11-30 | Пфайзер Инк. | НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| EP2886540B1 (en) * | 2012-08-14 | 2017-07-26 | Xuanzhu Pharma Co., Ltd. | Bicyclic substituted pyrimidine compounds |
| EP2884982B1 (en) | 2012-08-20 | 2017-09-20 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| WO2014048065A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| MX2015004801A (es) * | 2012-10-19 | 2015-08-14 | Hoffmann La Roche | Inhibidores de la syk. |
| PH12015501130B1 (en) | 2012-11-21 | 2023-01-27 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| EP2931281B1 (en) | 2012-12-12 | 2018-01-17 | Merck Sharp & Dohme Corp. | Amino-pyrimidine-containing spleen tyrosine kinase inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| SG11201505446WA (en) * | 2013-01-16 | 2015-08-28 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| US9708326B2 (en) | 2013-02-25 | 2017-07-18 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| US10130609B2 (en) | 2013-03-13 | 2018-11-20 | University Health Network | Pyrazole derivatives and their uses thereof |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| EP2988744A4 (en) | 2013-04-26 | 2016-11-02 | Merck Sharp & Dohme | THIAZOLSUBSTITUTED AMINOHETEROARYLE AS MILZTYROSINKINASE INHIBITOR |
| WO2014176216A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
| KR101657616B1 (ko) * | 2013-05-24 | 2016-09-19 | 주식회사유한양행 | 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법 |
| CN104177363B (zh) * | 2013-05-24 | 2018-06-05 | 江苏先声药业有限公司 | 双环杂环胺类Hedgehog信号通路抑制剂 |
| BR112016000195A8 (pt) | 2013-07-11 | 2019-12-31 | Acea Biosciences Inc | compostos heterocíclicos, composição farmacêutica, combinação, seu uso, e método para inibir uma atividade da tirosina quinase btk ou jak, egfr, alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, e suas respectivas vias |
| MX370588B (es) | 2013-08-30 | 2019-12-16 | Ptc Therapeutics Inc | Inhibidores de la bmi-1 de pirimidina sustituida. |
| RU2650512C2 (ru) | 2013-09-18 | 2018-04-16 | Бейджин Ханми Фармасьютикал Ко., Лтд. | Соединение, ингибирующее активности киназ ВТК и/или JAK3 |
| US10329270B2 (en) * | 2013-10-21 | 2019-06-25 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
| AU2014360446A1 (en) | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
| EP3083559B1 (en) | 2013-12-20 | 2021-03-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| WO2015094997A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| GB201401086D0 (en) * | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
| US9399637B2 (en) | 2014-03-28 | 2016-07-26 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| CN104086551B (zh) * | 2014-06-06 | 2016-09-21 | 人福医药集团股份公司 | 化合物及其制备方法和用途 |
| WO2016010886A1 (en) * | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| NZ629796A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9513297B2 (en) | 2014-12-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-Jun N-terminal kinase in skin |
| EP3712134B1 (en) | 2014-12-16 | 2023-11-29 | Signal Pharmaceuticals, LLC | Salts of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide |
| CA3199430A1 (en) | 2015-01-16 | 2016-07-21 | The General Hospital Corporation | Compounds for improving mrna splicing |
| EP3250557B1 (en) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| CN105837577B (zh) * | 2015-02-02 | 2019-01-25 | 四川大学 | 1-(嘧啶-4-基)3-胺基哌啶衍生物及其制备方法和用途 |
| US10913744B2 (en) * | 2015-02-13 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | LRRK2 inhibitors and methods of making and using the same |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN106188060A (zh) * | 2015-04-29 | 2016-12-07 | 厦门大学 | 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用 |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| ES2824576T3 (es) | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| BR112017027951A2 (pt) * | 2015-06-22 | 2018-08-28 | Ono Pharmaceutical Co., Ltd. | composto inibitório de brk |
| JP6853234B2 (ja) * | 2015-07-09 | 2021-03-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｂｔｋ阻害剤としてのピリミジン誘導体及びその使用 |
| WO2017011720A1 (en) * | 2015-07-16 | 2017-01-19 | Signal Pharmaceuticals, Llc | Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| EP3325432B1 (en) | 2015-07-24 | 2020-09-02 | Celgene Corporation | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
| US11021443B2 (en) | 2015-08-03 | 2021-06-01 | President And Fellows Of Harvard College | Charged ion channel blockers and methods for use |
| KR102048719B1 (ko) | 2015-08-13 | 2019-11-26 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Irak4억제제 및 이의 용도 |
| CN107531725B (zh) * | 2015-08-13 | 2021-03-19 | 北京韩美药品有限公司 | Irak4抑制剂及其应用 |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| WO2017059280A1 (en) * | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
| EP3359159B1 (en) | 2015-10-09 | 2023-06-07 | ACEA Therapeutics, Inc. | Pharmaceutical compositions of a pyrrolopyrimidine kinase inhibitor, and methods of making same |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017181285A1 (en) | 2016-04-21 | 2017-10-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Purine compounds and method for the treatment of cancer |
| PT3468972T (pt) | 2016-06-14 | 2020-08-21 | Novartis Ag | Compostos e composições para inibir a atividade da shp2 |
| ES2940911T3 (es) * | 2016-06-27 | 2023-05-12 | Rigel Pharmaceuticals Inc | Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4 |
| CN106187899B (zh) * | 2016-06-28 | 2019-07-16 | 绍兴文理学院 | 一种氟代氮杂芳烃的合成方法 |
| RU2714206C1 (ru) * | 2016-06-30 | 2020-02-13 | Даевунг Фармасьютикал Ко., Лтд. | Пиразолопиримидиновые производные в качестве ингибитора киназы |
| CN106349224A (zh) * | 2016-08-03 | 2017-01-25 | 山东大学 | 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用 |
| KR102477063B1 (ko) * | 2016-10-28 | 2022-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 |
| US11279703B2 (en) | 2016-12-01 | 2022-03-22 | Aptose Biosciences Inc. | Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof |
| US11052091B2 (en) | 2016-12-21 | 2021-07-06 | Ono Pharmaceutical Co., Ltd. | BRK inhibitory compound |
| CN110730678B (zh) | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
| EP3587422A4 (en) * | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE |
| AU2017408099A1 (en) | 2017-04-07 | 2019-11-07 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| KR20190043437A (ko) * | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| MA51431B1 (fr) * | 2017-12-28 | 2022-08-31 | Daewoong Pharmaceutical Co Ltd | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| JP2022523477A (ja) * | 2019-01-18 | 2022-04-25 | ボロノイ・カンパニー・リミテッド | ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物 |
| EP3915985A4 (en) | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US10828287B2 (en) | 2019-03-11 | 2020-11-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CN113811305A (zh) | 2019-03-11 | 2021-12-17 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CA3129089A1 (en) | 2019-03-11 | 2020-09-17 | Bridget Mccarthy Cole | Ester substituted ion channel blockers and methods for use |
| US11377422B2 (en) | 2019-03-11 | 2022-07-05 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020235902A1 (ko) * | 2019-05-17 | 2020-11-26 | 주식회사 보로노이 | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 |
| CN110317176A (zh) * | 2019-07-04 | 2019-10-11 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2020380118B2 (en) | 2019-11-06 | 2026-06-11 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CA3155568A1 (en) | 2019-11-06 | 2021-05-14 | Bridget Mccarthy Cole | Charged ion channel blockers and methods for use |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US11332446B2 (en) | 2020-03-11 | 2022-05-17 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| CN113717194B (zh) * | 2020-05-25 | 2026-03-20 | 上海翰森生物医药科技有限公司 | 杂芳类衍生物的盐及其制备方法 |
| CN115667228B (zh) * | 2020-05-25 | 2026-04-03 | 上海翰森生物医药科技有限公司 | 杂芳类衍生物的盐、晶型及其制备方法 |
| CN113717202B (zh) * | 2020-05-25 | 2025-10-17 | 上海翰森生物医药科技有限公司 | 杂芳类衍生物的自由碱晶型及其制备方法 |
| CN111892580B (zh) * | 2020-09-29 | 2021-02-05 | 北京鑫开元医药科技有限公司 | 一种2-氨基-4-(异吲哚啉-2-基)嘧啶-5-甲酰胺衍生物、制备方法及应用 |
| CN112107580A (zh) * | 2020-09-29 | 2020-12-22 | 北京鑫开元医药科技有限公司 | 一种脾酪氨酸激酶抑制剂的制剂组合物及其制备方法 |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| KR102585194B1 (ko) * | 2021-03-26 | 2023-10-10 | 주식회사 스탠다임 | Lrrk2에 대해 저해 활성을 갖는 신규한 페닐아미노피리미딘화합물 및 이의 용도 |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| EP4332104A4 (en) * | 2021-04-30 | 2025-04-16 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| US20250122202A1 (en) * | 2021-09-18 | 2025-04-17 | Shandong New Time Pharmaceutical Co., Ltd. | Egfr inhibitor, preparation method therefor and use thereof |
| US20250051337A1 (en) * | 2021-09-28 | 2025-02-13 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| CN116813550B (zh) * | 2022-03-28 | 2026-05-26 | 上海医药工业研究院有限公司 | 吲唑类衍生物、其制备方法、药物组合物及应用 |
| CN118005609B (zh) * | 2022-11-09 | 2025-06-17 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
| WO2025207825A1 (en) * | 2024-03-27 | 2025-10-02 | Gilead Sciences, Inc. | Stat6 degraders |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
| EP0872076B1 (de) * | 1995-05-19 | 2003-03-26 | Siemens Aktiengesellschaft | Verfahren zum rechnergestützten austausch kryptographischer schlüssel zwischen einer ersten computereinheit und einer zweiten computereinheit |
| US6316635B1 (en) | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| US6696448B2 (en) | 1996-06-05 | 2004-02-24 | Sugen, Inc. | 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors |
| US6316429B1 (en) | 1997-05-07 | 2001-11-13 | Sugen, Inc. | Bicyclic protein kinase inhibitors |
| US6486185B1 (en) | 1997-05-07 | 2002-11-26 | Sugen, Inc. | 3-heteroarylidene-2-indolinone protein kinase inhibitors |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
| JP2004504259A (ja) | 1998-06-30 | 2004-02-12 | パーカー ヒューズ インスティテュート | Ｊａｋ−３インヒビターを用いたｃ−ｊｕｎ発現の阻害方法 |
| AU5682799A (en) | 1998-08-21 | 2000-03-14 | Parker Hughes Institute | Quinazoline derivatives |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| US6841567B1 (en) | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| US6624171B1 (en) | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
| GB9904995D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Substituted aza-oxindole derivatives |
| US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US7655423B2 (en) | 1999-06-14 | 2010-02-02 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
| GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
| AU4903201A (en) | 1999-11-30 | 2001-07-03 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
| OA12118A (en) | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| US6610688B2 (en) | 1999-12-21 | 2003-08-26 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| AU2968701A (en) | 2000-01-24 | 2001-07-31 | Genzyme Corporation | Jak/stat pathway inhibitors and the uses thereof |
| JP4739632B2 (ja) | 2000-02-05 | 2011-08-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋのインヒビターとして有用なピラゾール組成物 |
| JP4783532B2 (ja) | 2000-02-05 | 2011-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋのインヒビターとして有用なピラゾール組成物 |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US6608048B2 (en) | 2000-03-28 | 2003-08-19 | Wyeth Holdings | Tricyclic protein kinase inhibitors |
| AR028261A1 (es) | 2000-03-28 | 2003-04-30 | Wyeth Corp | Inhibidores triciclicos de la proteina quinasa |
| OA12292A (en) | 2000-06-26 | 2003-11-11 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents. |
| AU2001229722A1 (en) | 2000-11-29 | 2002-06-11 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
| US20020115173A1 (en) | 2000-12-11 | 2002-08-22 | Children's Medical Center Corporation | Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity |
| PE20020776A1 (es) | 2000-12-20 | 2002-08-22 | Sugen Inc | Indolinonas 4-aril sustituidas |
| MXPA03005696A (es) | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
| FR2818642B1 (fr) | 2000-12-26 | 2005-07-15 | Hoechst Marion Roussel Inc | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion |
| WO2002060492A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
| AUPR279101A0 (en) | 2001-01-30 | 2001-02-22 | Cytopia Pty Ltd | Protein kinase signalling |
| IL159120A0 (en) * | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| CA2450769A1 (en) | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
| AU2002334355A1 (en) | 2001-09-06 | 2003-03-18 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
| JP2005506982A (ja) | 2001-09-10 | 2005-03-10 | スージェン・インコーポレーテッド | キナーゼ阻害剤としての３−（４，５，６，７−テトラヒドロインドール−２−イルメチリデン）−２−インドリノン誘導体 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| PY0228255A (es) | 2001-12-06 | 2004-06-01 | Pfizer Prod Inc | Compuestos cristalinos novedosos |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| US7459455B2 (en) | 2002-02-08 | 2008-12-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
| CA2477505A1 (en) | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| CN1665808A (zh) | 2002-05-06 | 2005-09-07 | 沃泰克斯药物股份有限公司 | 噻二唑或噁二唑及其作为jak蛋白激酶抑制剂的用途 |
| WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| CA2487679A1 (en) | 2002-05-30 | 2003-12-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
| AU2003276125B2 (en) | 2002-06-17 | 2007-05-17 | Smithkline Beecham Corporation | Chemical process |
| IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| AU2003262642B2 (en) | 2002-08-14 | 2010-06-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| EP1562911B1 (en) | 2002-11-01 | 2010-01-06 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
| US7259161B2 (en) | 2002-11-04 | 2007-08-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| US7348335B2 (en) | 2002-11-05 | 2008-03-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| RS20050380A (sr) | 2002-11-21 | 2007-11-15 | Pfizer Products Inc., | Derivati 3-aminopiperidina i postupci njihove proizvodnje |
| WO2004047843A1 (en) | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Method of treatment of transplant rejection |
| US7226919B2 (en) | 2002-12-18 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Compositions useful as inhibitors of protein kinases |
| US7547794B2 (en) | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| CN100457728C (zh) | 2003-07-24 | 2009-02-04 | 麦克公司 | 酪氨酸激酶抑制剂 |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| EA200600225A1 (ru) | 2003-08-14 | 2006-08-25 | Пфайзер Инк. | Производные пиперазина для лечения вич инфекций |
| ATE542801T1 (de) | 2003-08-15 | 2012-02-15 | Novartis Ag | Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| ES2295924T3 (es) | 2003-10-03 | 2008-04-16 | Pfizer, Inc. | Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion. |
| DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| ES2389203T3 (es) | 2004-01-12 | 2012-10-24 | Ym Biosciences Australia Pty Ltd | Inhibidores de quinasa selectivos |
| GB0407723D0 (en) | 2004-04-05 | 2004-05-12 | Novartis Ag | Organic compounds |
| JP4876915B2 (ja) | 2004-06-14 | 2012-02-15 | 日本電気株式会社 | フィルム外装電気デバイス |
| ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| JP2008540436A (ja) * | 2005-05-03 | 2008-11-20 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋキナーゼインヒビターおよびそれらの使用 |
| JP2009511527A (ja) | 2005-10-13 | 2009-03-19 | グラクソ グループ リミテッド | Ｓｙｋ阻害物質としてのピロロピリミジン誘導体 |
| EP1960372B1 (en) * | 2005-12-15 | 2015-12-09 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| WO2008009458A1 (en) | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| EP2142550A1 (en) * | 2007-04-02 | 2010-01-13 | Palau Pharma, S.A. | Pyrrolopyrimidine derivatives as jak3 inhibitors |
-
2009
- 2009-04-22 BR BRPI0910668A patent/BRPI0910668A2/pt not_active IP Right Cessation
- 2009-04-22 AU AU2009238590A patent/AU2009238590A1/en not_active Abandoned
- 2009-04-22 CA CA2723185A patent/CA2723185A1/en not_active Abandoned
- 2009-04-22 NZ NZ588830A patent/NZ588830A/xx not_active IP Right Cessation
- 2009-04-22 EP EP09734422.0A patent/EP2271631B1/en active Active
- 2009-04-22 CN CN2009801223945A patent/CN102066338A/zh active Pending
- 2009-04-22 CN CN2013100825419A patent/CN103224497A/zh active Pending
- 2009-04-22 JP JP2011506293A patent/JP2011518219A/ja not_active Withdrawn
- 2009-04-22 US US12/386,848 patent/US8258144B2/en active Active
- 2009-04-22 WO PCT/US2009/002512 patent/WO2009131687A2/en not_active Ceased
-
2010
- 2010-10-14 IL IL208719A patent/IL208719A0/en unknown
-
2012
- 2012-06-20 US US13/528,709 patent/US9139581B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011518158A5 (cg-RX-API-DMAC10.html) | ||
| CA2671744A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| TWI455715B (zh) | ４－（４－氰基－２－硫基芳基）二氫嘧啶酮類及其用途 | |
| ES2361146T3 (es) | Derivados de la piramidina inhibitatoria de vih. | |
| JP2018522823A5 (cg-RX-API-DMAC10.html) | ||
| AU2009238590A1 (en) | Inhibitors of protein kinases | |
| HRP20171913T1 (hr) | Aminopirimidinilni spojevi kao inhibitori jak | |
| JP2004536814A5 (cg-RX-API-DMAC10.html) | ||
| BG64702B1 (bg) | Hiv инхибиращи пиримидинови производни | |
| HRP20140265T1 (hr) | Derivat aminopirazina i odgovarajuä†i lijek | |
| JP2010535824A (ja) | Ｄｈｏｄｈ阻害剤としてのアザビフェニルアミノ安息香酸誘導体 | |
| JP2013523710A5 (cg-RX-API-DMAC10.html) | ||
| CZ293752B6 (cs) | Antagonisty faktoru uvolňujícího kortikotropin | |
| AU2005289426A1 (en) | Substituted heterocyclic compounds and methods of use | |
| AU2005249382A1 (en) | Monocyclic heterocycles as kinase inhibitors | |
| JP2017515836A5 (cg-RX-API-DMAC10.html) | ||
| RU2014147191A (ru) | Амидопроизводные как блокаторы ttx-s | |
| JP2017530199A5 (cg-RX-API-DMAC10.html) | ||
| JP2016540803A5 (cg-RX-API-DMAC10.html) | ||
| JP2013519733A5 (cg-RX-API-DMAC10.html) | ||
| JP2015520232A5 (cg-RX-API-DMAC10.html) | ||
| RU2012154308A (ru) | Пиперидинил-замещенные лактамы как модуляторы gpr119 | |
| NO328144B1 (no) | Pyrimidinforbindelser og farmasoytisk preparat | |
| JP2014523414A5 (cg-RX-API-DMAC10.html) | ||
| JP2023527698A (ja) | 新規マロニトリル誘導体 |